Santhera Eyes US Market Potential After DMD Candidate Tests Positive

Top-Line Phase IIb Results For Vamorolone

01 Jun 2021

• By John Davis

Just under a year since Santhera restructured after disappointing late-stage clinical results with another DMD candidate, the Switzerland-headquartered company has reported positive top-line results in the condition with licensed-in vamorolone, and is planning for commercialization in late 2022/early 2023.

Santhera Pharmaceuticals and Reveragen BioPharma, Inc. have reported positive top-line Phase IIb results for vamorolone in Duchenne muscular dystrophy, in which the potential first-in-class dissociative steroid had few side effects and improved muscle function, moving the compound nearer the marketplace.

Concerns about the side effects of conventional steroid therapy in young children, which include the stunting of growth, can hold...